Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities: 2021

  • Amylyx Pharmaceuticals' Preferred Stock Liabilities was N/A to $239.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $239.4 million, marking a year-over-year change of. This contributed to the annual value of $239.4 million for FY2021, which is N/A change from last year.
  • As of Q4 2021, Amylyx Pharmaceuticals' Preferred Stock Liabilities stood at $239.4 million.
  • Over the past 5 years, Amylyx Pharmaceuticals' Preferred Stock Liabilities peaked at $239.4 million during Q4 2021, and registered a low of $239.4 million during Q4 2021.
  • Over the past 1 years, Amylyx Pharmaceuticals' median Preferred Stock Liabilities value was $239.4 million (recorded in 2021), while the average stood at $239.4 million.